Novo Nordisk A/S
NVOOf the 86 managers this site tracks, 4 held Novo Nordisk (NVO) in their latest 13Fs, most of them for Q2 2026. Against the quarter before, 2 added or bought in and 2 reduced or sold out. No Form 4 has been filed by Novo Nordisk (NVO) insiders in the past year. No Schedule 13D or 13G is on file for NVO from the activists and large holders the site follows.
Every 13F filer's holdings of NVO are not in yet — they come from SEC's quarterly 13F data sets. Meanwhile, the superinvestors the site tracks:
Superinvestors
| Manager | Quarter | Shares | Move | Value |
|---|---|---|---|---|
| Dodge & Cox · Dodge & Cox | Q2 2026 | 20.4M | added +6% | $977.8M |
| Thomas Gayner · Markel Group Inc. | Q3 2026 | 2.9M | held | $108.8M |
| Sarah Ketterer · Causeway Capital Management LLC | Q2 2026 | 1.7M | added +43% | $80.4M |
| Lee Ainslie · Maverick Capital Ltd | Q2 2026 | 1.7M | reduced −20% | $79.3M |
| Francois Rochon · Giverny Capital Inc. | Q2 2026 | — | sold | sold out |
A 13F is a quarterly snapshot filed up to 45 days after quarter end; 13D/13G are filed above 5%; a Form 4 within two business days of a trade. Insider holdings are the shares each person holds directly — trusts, family and other indirect holdings are reported on lines of their own and are not added in. Codes are the SEC's: P open-market purchase, S open-market sale; M exercise, F tax withholding, A grant and G gift are routine. A 10b5-1 flag means the trade ran under a plan adopted in advance. Superinvestor names link to their full books under Investors; method notes in the manual.